Table 3.
Ongoing clinical studies combining AA and immunotherapies in RCC.
| Study Name | Targeting Agents | Comparison | Phase | Primary Endpoint | Therapy Setting | Status * | NCT Number |
|---|---|---|---|---|---|---|---|
| WO29637 | atezolizumab + bevacizumab | sunitinib | III | PFS, OS | First line | Active Not recruiting | NCT02420821 |
| JAVELIN Renal 101 | avelumab + axitinib | sunitinib | III | PFS | First line | Recruiting | NCT02684006 |
| JAVELIN Renal 100 | avelumab + axitinib | / | I | MTD | First line | Active Not recruiting | NCT02493751 |
| 200249 | pembrolizumab + pazopanib | monotherapy | II | Clinical efficacy and safety | First line | Active Not recruiting | NCT02014636 |
| KEYNOTE-426 | pembrolizumab + axitinib | sunitinib | III | PFS, OS | First line | Recruiting | NCT02853331 |
| E7080-G000-307 | lenvatinib + pembrolizumab or everolimus | sunitinib | III | PFS | First line | Recruiting | NCT02811861 |
| N.a. | pembrolizumab + axitinib | / | Ib | Safety, treatment efficacy | First line | Active | NCT02133742 |
| N.a. | pembrolizumab + lenvatinib | / | Ib/II | MTD, ORR | No standard therapies anymore available | Active | NCT02501096 |
| BTCRC-GU14-003 | pembrolizumab + bevacizumab | / | Ib/II | Safety, efficacy tolerability | At least second line | Active Not recruiting | NCT02348008 |
| N.a. | atezolizumab + MOXR0916 + bevacizumab | atezolizumab + MOXR0916 | I | Dose limiting toxicities Side effects | Any | Recruiting | NCT02410512 |
| CheckMate 016 | nivolumab + sunitinib or pazopanib or ipilimumab | nivolumab | I | Safety tolerability | First line Second line |
Recruiting | NCT01472081 |
| N.a. | cabozantinib + nivolumab | cabozantinib + nivolumab + ipilimumab |
I | Safety tolerability | No standard therapies anymore available | Recruiting | NCT02496208 |
| IMmotion150 | atezolizumab +/−bevacizumab | sunitinib | II | PFS | First line | Active Not recruiting | NCT01984242 |
* status according to https://clinicaltrials.gov/, accessed on 8 July 2017. ORR, objective response rate.